Apotex Allies: Amgen's Views Distort Congress' Biosimilars Goals
This article was originally published in Scrip
Executive Summary
If a Florida district court's ruling is upheld granting Amgen Inc.'s motion for a preliminary injunction (PI) blocking Apotex Inc. from marketing its pegfilgrastim biosimilar for 180 days after US approval, it would distort Congress' intent in enacting the Biologics Price Competition and Innovation Act (BPCIA), supporters of the latter company's views said in friend-of-the-court briefs.